XETRA · MRK.DE
Merck KGaA
€151.30+€1.00 (+0.67%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
Loading market information…
SIX · SDZ.SW · CHF
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Sandoz Group AG’s quoted price sits in the upper half of its reported 52-week range, 3.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sandoz Group AG’s forward annual dividend is CHF 0.80 per share, paid annual. The forward yield is 0.97% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Sandoz Group AG’s next earnings report is currently expected on Feb 17, 2027, with estimated earnings per share of CHF 1.88. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sandoz Group AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 31, 2026, 02:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2023 | May 7, 2024 | -CHF 0.15 | CHF 2.12B |
|---|
| Q2 2023 | Sep 30, 2023 | CHF 0.49 | CHF 4.41B |
|---|
| Q4 2022 | Dec 31, 2022 | CHF 0.88 | CHF 4.63B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€151.30+€1.00 (+0.67%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
₪128.00+₪0.80 (+0.63%)
Teva Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 2.07% below the high.
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
$19.04-$0.17 (-0.86%)
Viatris Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
₹4,613.40+₹33.40 (+0.73%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.13% below the high.
₹1,352.00+₹7.00 (+0.52%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.45% below the high.
₹1,378.90+₹20.90 (+1.54%)
Cipla Limited’s quoted price sits in the upper half of its reported 52-week range, 10.44% below the high.
₹2,492.80+₹23.50 (+0.95%)
Mankind Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 5.65% below the high.
